A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

NCT05906992 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

BIOLOGICAL: CT-P53
BIOLOGICAL: US-Ocrevus
BIOLOGICAL: EU-Ocrevus

Sponsor

Celltrion